Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy With or Without Famitinib in Neoadjuvant TNBC
NCT05999149Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of famitinib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoint: Pathological Complete Response rate at 24 weeks. Started Aug 2023; status: recruiting.
02
Drugs
famitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05999149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999149.